NICHE BIOPHARMACEUTICALS LLC

• Niche Biopharmaceuticals has invented a Coupled Anti-infected Immunomodulatory Therapeutic (CAIT)
with activity in the ug/mL range against over 40 different bacterial organisms.
• CAIT is also potent against envelope viruses such as SARS-CoV-2 and influenza.
• Bacteria have been shown to be unable to develop resistance to our class of compounds over 52 weeks of culture at 50% of the minimum bactericidal concentration (MBC).
• CAIT are anti-inflammatory.
• Three broad composition of matter and use patents have issued US11365176, US11572342, US11873272.
• Code named NB2 is a new chemical entity per FDA regulations, meaning that it has never been synthesized until Niche was able to create the molecule.
• NicheBio is focusing its initial efforts on Atopic dermatitis.
• This initial market is greater than $2-5 billion per year in the United States.
• Future markets opportunities would cover the other potential many indications.
• A pre-IND meeting was conducted with FDA in May 2024.
• We are looking to raise $5 million to take us through the phase 1 clinical trial.

Address and contact information:

Niche Biopharmaceuticals LLC
22345 Bracketts Road
Shorewood, MN 55331 USA

Founder and Chairman: Dayton T. Reardan, Ph.D., RAC
Contact email: Info@NicheBiopharma.com

Niche Biopharmaceuticals LLC is an early stage Limited Liability Company registered in the state of Delaware doing business in Minnesota.